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a b s t r a c t
Current inﬂuenza vaccines induce strain-speciﬁc immunity to the highly variable hemagglutinin (HA)
protein. It is therefore a high priority to develop vaccines that induce broadly cross-protective immunity
to different strains of inﬂuenza. Since inﬂuenza A M2 proteins are highly conserved among different
strains, ﬁve tandem repeats of the extracellular peptide of M2 in a membrane-anchored form on virus-
like particles (VLPs) have been suggested to be a promising candidate for universal inﬂuenza vaccine.
In this study, ferrets were intramuscularly immunized with 2009 H1N1 split HA vaccine (“Split”) alone,
inﬂuenza split vaccine supplemented with M2e5x VLP (“Split+M2e5x”), M2e5x VLP alone (“M2e5x”),
or mock immunized. Vaccine efﬁcacy was measured serologically and by protection against a sero-
logically distinct viral challenge. Ferrets immunized with Split+M2e5x induced HA strain speciﬁc and
conserved M2e immunity. Supplementation of M2e5x VLP to split vaccination signiﬁcantly increased the
immunogenicity of split vaccine compared to split alone. The Split+M2e5x ferret group showed evidence
of cross-reactive protection, including faster recovery from weight loss, and reduced inﬂammation, as
inferred from changes in peripheral leukocyte subsets, compared to mock-immunized animals. In addi-
tion, ferrets immunized with Split+M2e5x shed lower viral nasal-wash titers than the other groups.
Ferrets immunized with M2e5x alone also show some protective effects, while those immunized with
split vaccine alone induced no protective effects compared to mock-immunized ferrets. These stud-
ies suggest that supplementation of split vaccine with M2e5x-VLP may provide broader and improved
cross-protection than split vaccine alone.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://. Introduction
Infection with inﬂuenza A virus is a signiﬁcant cause of
orbidity and mortality worldwide [1–3]. Vaccination is the
ost cost-effective measure to prevent inﬂuenza disease and its
ortality. Current inﬂuenza vaccines are basedprimarily on immu-
ity to the highly variable hemagglutinin antigen, and induce
train-speciﬁc immunity. Consequently, inﬂuenza vaccine must be
pdated frequently to match circulating viruses. In addition, novel
nﬂuenza A strains such as reassortantswith avian or swine strains,
hich occasionally enter the human population and represent a
otential pandemic threat, are not protected against by current
∗ Corresponding authors. Tel.: +1 4046397286.
E-mail addresses: ite1@cdc.gov (I.A. York), skang24@gsu.edu (S.-M. Kang).
ttp://dx.doi.org/10.1016/j.vaccine.2015.12.023
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-Ncreativecommons.org/licenses/by-nc-nd/4.0/).
vaccines. The emergence of the triple-reassortant 2009 pandemic
H1N1 virus (A(H1N1)pdm09) is an example of a new inﬂuenza
strain with distinct antigenic properties [4]. Although the hemag-
glutinin (HA) protein from this strain is of the H1 subtype, many
decades of separate evolution in swine versus humans led to this
strain becoming antigenically distinct from the seasonal A(H1N1)
which circulated in humans before 2010 [5]. Accordingly, standard
assays such as hemagglutination inhibition (HI) and virus neutral-
ization assays showed no cross-reactive immunity between these
strains, and the pandemic of 2009–2010 demonstrated that prior
exposure to seasonal H1N1 viruses or vaccines conferred little or
no protection against A(H1N1)pdm09 viruses. Therefore, inﬂuenza
vaccines capable of inducing broad, cross-protection against differ-
ent inﬂuenza variants or strains need to be developed.
The extracellular domain of the inﬂuenza A ion-channel protein
M2 is well conserved across inﬂuenza A subtypes [6,7] and is one
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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otential target for a universal inﬂuenza A vaccine [8–11]. M2 has
small size extracellular domain containing 23 amino acids (M2e)
nd low immunogenicity even in a conjugate to carrier molecules
nd in the presence of adjuvants [12]. We have previously shown
hat inﬂuenza M2 full-length proteins incorporated into virus-like
articles (VLPs) conferred cross protection against antigenically
ifferent inﬂuenza viruses but M2 immunogenicity was low [13].
o improve the efﬁcacy of M2e-based VLP vaccines, we generated
ve tandem repeats of M2e from human, swine, and avian origin
nﬂuenza A viruses in a membrane-anchored form to be expressed
n VLPs (M2e5x VLP), resulting in enhanced cross protection in
ice [14].
The ferret remains the most widely accepted small animal
odel for inﬂuenza virus infection and vaccine protection studies
15–18]. In this present study,wedemonstrate thatM2e5xVLPwas
mmunogenic in ferrets and supplementation of split vaccine with
2e5x VLPs could further enhance cross-protective immunity.
. Materials and methods
.1. Viruses
A/Brisbane/59/2007 (BR/59), an A(H1N1) human sea-
onal inﬂuenza virus, and A/California/08/2009 (CA/08), an
(H1N1)pdm09 2009 pandemic H1N1 virus, were used in these
xperiments. Although these viruses both are in the A(H1N1)
ubtype, they are serologically distinct and conventional inactiv-
ted vaccines against one do not lead to cross-protection against
he other. Virus stocks were propagated in the allantoic cavity of
mbryonated chicken eggs as previously described [19]. Stocks
ere titered in a standard plaque assay using Madin-Darby Canine
idney cells as described [4] and expressed as plaque forming units
pfu) [20]. CA/08 and BR/59 were used as antigens for serological
esting in hemagglutination inhibition (HI) assay.
.2. Vaccines
The M2e5X VLP containing heterologous M2e tandem repeat
as constructed and produced using the recombinant baculovirus
rBV) expression system as previously described [14]. Brieﬂy, Sf9
nsect cells were co-infected with recombinant baculoviruses co-
xpressing inﬂuenza virus M1 matrix protein and a tandem repeat
f heterologous M2e (M2e5x). Culture supernatants containing
eleased M2e5x VLP were harvested, and M2e5x VLP vaccine was
uriﬁed using sucrose-gradient ultracentrifugation. Commercial
uman A(H1N1)pdm09 split vaccine was derived from the 2009
andemic strain of A/California/07/2009 virus (CA/07) and kindly
rovided by Green Cross (South Korea). Potency of the split vaccine
as assessed by single radial immunodiffusion (SRID) with CA/07
eference serumand antigen obtained from the Center for Biologics
valuation and Research of the U.S. Food and Drug Administration
Kensington, MD).
.3. Ferret immunization and viral challenge
All animal experiments were performed under the guidance
f the Centers for Disease Control and Prevention’s Institutional
nimal Care and Use Committee and were conducted in an Associ-
tion for Assessment and Accreditation of Laboratory Animal Care
nternational-accredited animal facility.Male Fitch ferrets (Mustela
utorius furo), about 6 months of age (Triple F Farms, Sayre, PA),
erologically negative for currently circulating inﬂuenza viruses,
ere used in this study.
Brieﬂy, groups of ﬁve ferrets were immunized with M2e5X
LPs alone; conventional monovalent split vaccine against
(H1N1)pdm09; a combination of M2e5X VLP and split vaccine;4 (2016) 466–473 467
or mock immunized with PBS. Ferrets were injected intramuscu-
larly with immunogens (5g of HA or 100g of M2e5X VLP total
protein) diluted in a total of 0.25ml sterile phosphate-buffered
saline (PBS). Immunizations with split vaccine were repeated so
that the split vaccine alone group elicitedHI titers thatwere similar
and greater than 40 (see Fig. 1 for timing of immunizations). After
immunization, ferrets were challenged with the seasonal human
inﬂuenza strain BR59. Although CA/08 and BR/59 are both in the
A(H1N1) subgroup, these strains have diverged extensively and
conventional split vaccines do not confer cross-protection between
these strains [5]. After challenge, clinical signs of infection (changes
in body weight and temperature), concentration of virus shed in
nasal washes, and changes in peripheral blood leukocyte frequen-
cies were measured for 14 days.
2.4. Viral challenge
Fourteen days after the last immunization, all animals were
challenged intranasally with 0.5ml PBS containing 1×106 PFU of
BR/59. Ferrets were monitored for changes in body weight and
temperature as well as clinical signs of illness (sneezing, lethargy,
nasal discharge, diarrhea and neurological dysfunction) on a daily
basis for two weeks. Body temperatures were measured using
an implantable subcutaneous temperature transponder (BioMedic
Data Systems, Inc., Seaford, DE). On days 0–7, 9, 11, and 13
post-challenge, animals were anesthetized and blood samples
of 200–250l taken from the cranial vena cava as previously
described [19]. Nasal washes were collected with 1ml of PBS on
days 0–7, and 9 (Fig. 1). Virus titers were determined by a plaque
assay in MDCK cells and expressed as log10 PFU in 1ml of nasal
washes. The limit of virus detection was 100PFU per 1ml of nasal
washes.
2.5. Serology
HI assays were performed as previously described [21]. HI titers
against CA/08, and BR/59 were assessed and expressed as the
reciprocal of the highest dilution of the samples inhibiting hemag-
glutination.
M2e-speciﬁc serum antibody responses were determined by
ELISA using synthetic human peptides (2g/ml) as a coat-
ing antigen as previously described [13,14]. Brieﬂy, horseradish
peroxidase-conjugated goat anti-ferret IgG (KPL, Inc Gaithersburg,
Maryland USA) was used as the secondary antibody to determine
total IgGantibodies. The substrate TMB (eBioscience, SanDiego, CA)
was used to develop color and 1M H3PO4 was used to stop devel-
oping color reaction. The optical density at 450nm was read using
an ELISA reader.
2.6. Antibodies, preparation of leukocytes and ﬂow cytometry
Flow cytometry assays were performed as previously described
[19]. Brieﬂy, peripheral blood was collected in tubes containing
EDTA and red blood cells lysed with erythrocyte lysing solution
(0.15M NH4Cl, 10mM KHCO3, and 1mM EDTA pH 7.3). Cells were
stained with monoclonal antibodies recognizing CD4 (clone 02,
Sino Biological Inc., Beijing, China), CD8 (clone OKT8, eBioscience,
San Diego, CA) CD11b (clone M1/70, eBioscience), CD3 (clone
PC3/188A, Santa Cruz Biotechnology, Santa Cruz, CA), and CD79a
(clone HM47, eBioscience). Data were acquired on a FACSCanto II
ﬂow cytometer (BD Bioscience, San Jose, CA), and analyzed using
FlowJo software (Tree Star, Ashland, OR).
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.7. Statistical analysis
Statistical signiﬁcance and 95% conﬁdence intervals were cal-
ulated using a linear mixed model with repeated measures,
mplemented in the SAS program. Compound symmetry was used
or the covariance structure for ﬂow cytometry values; unstruc-
ured covariance was used for the HI titers. Conﬁdence intervals
ere calculated using compound symmetry covariance to pool
ariability between groups. A p value <0.05 was used as the cutoff
or statistical signiﬁcance. The experiments were repeated twice.
ost-challenge data were analyzed both as separate experiments
nd as merged data, with very similar results; ﬁgures shown here
re from merged data.
. Results
.1. Immunogenicity
Groups of ferrets were intramuscularly immunized with M2e5x
LP alone (M2e5x), split vaccine alone (Split), or supplemented
plit vaccine with M2e5x VLP (Split+M2e5x) as summarized in
ig. 1. Ferrets showed detectable anti-M2e antibody responses
1 days even after a single immunization with M2e5x VLP, with
r without split vaccine (M2, Fig. 2A). Second and third immun-
zations with M2e5x VLP further at day 21 and 35 respectively
ncreased antibodies speciﬁc for M2e antigens (days 35 and 47,
2e5x, Fig. 2A). After the 2nd boost immunization (day 35), there
as no more M2e5x VLP immunization. Although M2e antibody
iters dropped slightly in the 9 weeks (day 61, Fig. 2A), levels of
nti-M2 antibodies remained high and easily detectable at the time
f challenge.
Ferrets immunized with split vaccine alone showed moderate
evels of HI antibodies titers that ranged from <10 to 40 (geometric
ean titer [GMT] =30)onlyafter the3rd immunization (Fig. 2B) and
ere further boosted with a 4th immunization with split vaccine,
esulting in HI titers of 40 to 320 (GMT=139).
Interestingly, ferrets that received supplemented split vaccina-
ion with M2e5x VLP induced signiﬁcant levels of vaccine virus
peciﬁc antibody responses even after primary immunization,
eaching HI titers of 40 to 80 (GMT=53, day 21, Split+M2e5x,
 esahp noitazinummI
Days post-challenge 
Days post-prime 0 21 35 47
Immunization
M2e5x √ √ √
Split √ √ √
Split+M2e5x √ √ M2e5x only
Naïve (PBS) √ √ √
Serology
ELISA √√√√
HI √√√√
Challenge BR/59
Clinical signs
Nasal wash
PBL analysis
Body weight
Temp
Temperature
ig. 1. Outline of experimental protocol. Male Fitch ferrets (N=5 per group) were imm
1N1pdm09, a combination of M2e5X and split vaccine, or mock immunized with PBS
nimals were challenged with 106 PFU of inﬂuenza A/Brisbane/59/2007 (BR/59). Body wei
nalysis of peripheral blood leukocytes (PBL) on days 0–7, 9, 11 and 13 relative to day of c
t intervals as shown.4 (2016) 466–473
Fig. 2B). After two immunizations, the M2e5x VLP supplemented
ferret group reached high levels of HI titers, ranged from160 to 320
(GMT=184 day 35, Fig. 2B). These results suggest that M2e5x VLPs
appear to act as an adjuvant role in increasing HI titers of vaccine,
reaching higher levels at early time points. The adjuvant effect of
theM2e5xVLPwasbalancedby repeatedadministrationof the split
vaccine alone (Fig. 1). As HAneutralizing antibody is the best estab-
lished correlate of protection for inﬂuenza, animals receiving split
vaccine only were immunized until CA/08 HI titers reached HI lev-
els comparable to those in animals receiving SplitM2e5x (Fig. 2B).
Prior to challenge, ferrets in both the split and Split+M2e5x groups
demonstrated CA/08 HI titers ranging from 80 to 320 with GMTs of
139 and 160, respectively, which is expected to confer protection
against homologous virus.
3.2. Clinical signs after viral challenge
The major focus of this study was to determine the efﬁcacy of
M2e5xVLPandsupplementedvaccination (Split+M2e5x) in confer-
ring cross protection. As expected, all naïve and vaccinated animals
were seronegative for the challenge virus BR/59 prior to challenge
(Fig. 2C), as well as to currently circulating B and H3 strains (not
shown). Clinical signs of lethargy, sneezing, and nasal discharge
were minor and did not differ between groups. All ferrets exhib-
ited a spike in body temperature one day post-challenge with
BR/59, followed by a reduction in temperature by day two (Fig. 3A).
Although body temperatures ﬂuctuated throughout the course of
the experiment, as is typical of ferrets [22], no consistent trends
were observed after day one (Fig. 3A).
All treatment groups lost at least 5% of their body weight over
the ﬁrst 2 days of infection. Beyond 2 days post-challenge, ferrets
immunized with supplemented Split+M2e5x demonstrated signif-
icantly less weight loss and more rapid recovery than all other
groups (Fig. 3B).
Virus replication in the upper respiratory tract was determined
by titratingnasalwashes. Peak viral sheddingwas observed at day1
post-challenge for all animals (Fig. 4). All groups shed similar titers
of virus during the ﬁrst 3 days. However, from days 4 on, ferrets
immunized with Split+M2e5x had signiﬁcantly lower viral nasal
wash titers than other groups (Fig. 4), and from day 5 on, ferrets
esahp egnellahC
-3 0 1 2 3 4 5 6 7 9 11 13 14
50 61 64 65 66 67 68 69 70 71 73 75 77 78
√
√√√√
√√√√
√
√ √ √ √ √ √ √ √ √
√ √ √ √ √ √ √ √ √ √ √
Daily
Daily 
unized with M2e5X-VLPs alone, conventional monovalent split vaccine against
, and received booster immunizations as indicated. On day 64 after priming, all
ght and temperature was monitored as indicated. Blood samples were collected for
hallenge. To assess antibody responses (HI and ELISA assays), serum were collected
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mmunized with M2e5x alone shed signiﬁcantly lower viral titers
han did ferrets immunized with split vaccine alone or with PBS.
f eight ferrets included in both experiments, only three immu-
ized with Split+M2e5x shed virus by day 6 post-challenge, and
ll completely cleared virus by day 7 post-challenge. In the group
mmunized with M2e5x alone, six ferrets shed virus by day 6, and
ll ferrets were clear of virus by day 7 post-challenge. All ferrets
eceiving PBS or split vaccine alone shed virus at day 6 post chal-
enge, while one ferret immunized with split vaccine shed virus by
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ig. 2. Serological response to immunization. (A) The antibody response against to M2e
emagglutination inhibition (HI) serumantibody titersweremeasuredusing (B) A/Californ
M2e5x”, vaccinated animalswithM2e5xVLPs alone; “Split”, vaccinated animalswithmon
nimals with monovalent 2009 H1N1 split inactivated virus vaccine supplemented with
≤0.05; † p≤0. 001). Error bars represent 95% conﬁdence intervals, calculated using com
anels B and C represents the limit of detection (HI titers =10).4 (2016) 466–473 469
day 7 post-challenge and three ferrets receiving PBS still shed virus
at this time point (Fig. 4). All groups completely cleared the virus
by day 9 post-challenge.
3.3. Serological changes after challengeFollowing challenge, animals immunized with vaccines con-
taining M2e5x increased M2e-speciﬁc antibody responses (M2e5x,
Split+M2e5x, Fig. 2A), while anti-M2e titers in animals vaccinated
nization
61 64 71 78
*
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*
Challenge 
61 64 71 78
61 64 71 78
*
*†
†
† †
†
†
†
† ††
†
†
†
†
†
† †
†
†
†
†
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peptide was measured by an ELISA using synthetic human peptides. (B) and (C)
ia/08/2009 (H1N1pdm), or (C) A/Brisbane/59/2007. “Naïve”, unvaccinated animals;
ovalent 2009H1N1 split inactivated virus vaccine alone; “Split+M2e5x”, vaccinated
M2e5x VLPs. A p value <0.05 was used as the cutoff for statistical signiﬁcance (*
pound symmetry covariance to pool variability across groups. The dashed line in
470 N. Music et al. / Vaccine 34 (2016) 466–473
Fig. 3. Clinical responses to infection. Ferrets were challenged with 106 PFU of BR/59 intranasally 64 days after the initial immunization. (A) Body temperature and (B) body
weight were recorded daily, including three days prior to challenge to establish baseline values. Data shown are normalized to the individual animals’ weight or temperature
on the day of challenge (day 0), and group averages are shown. “Naïve”, unvaccinated animals; “M2e5x”, vaccinated animals with M2e5x VLPs alone; “Split”, vaccinated
animals with monovalent 2009 H1N1 split inactivated virus vaccine alone; “Split+M2e5x”, vaccinated animals with monovalent 2009 H1N1 split inactivated virus vaccine
s me po
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nupplemented with M2e5x VLPs. Statistical signiﬁcance is indicated above each ti
2+Split compared to split alone; S+M2vN: M2+Split compared to unvaccinated an
vN: split alone compared to unvaccinated animals. Error bars represent 95% conﬁd
ith split vaccine only, or mock immunized, showed little or no
erological response toM2 (Fig. 2A). HI antibody titers to BR/59 also
ncreased for all groups by days 7 and 14 post-challenge (Fig. 2C).
errets that received vaccines containing the M2e5x VLP produced
igniﬁcantly higher HI titers at days 7 and 14 post challenge than
he split alone group (Split +M2e5x,M2e5x, Fig. 2C). Ferrets receiv-
ng vaccines containing split CA/08 modestly increased HI titers to
A/08 upon BR/59 challenge; in the other groups, anti-CA/08 titers
emained unchanged after challenge (Fig. 2B).
In addition, we tested all sera collected after the full immu-
ization regimen (challenge day 0) as well as on days 7 and 14int (* p≤0.05; † p≤0.001): S+M2vM2, M2+Split compared to M2 alone; S+M2vS:
M2vS: M2 compared to split alone; M2vN: M2 compared to unvaccinated animals;
intervals.
post-challenge for HI activity against a number of H3, H5 and
H7 subtype viruses (data not shown). As expected, neither the
combination of M2 and inactivated vaccine (challenge day 0), nor
exposure to challenge virus (days 7 and 14 post-challenge) induced
HI cross-reactivity with any of these distantly-related strains.
3.4. Changes in leukocyte subsets after challengeA marked, transient lymphopenia and granulocytosis was
apparent in all treatment groups 1 and 2 days post-challenge
(Fig. 5A–D). Both groups receiving M2e5x VLPs exhibited an earlier
N. Music et al. / Vaccine 34 (2016) 466–473 471
Fig. 4. Virus shedding following infection. Virus titers in ferret nasal washes were determined on days 1–7 and 9 post-challenge. “Naïve”, unvaccinated animals; “M2e5x”,
vaccinated animals with M2e5x VLPs alone; “Split”, vaccinated animals with monovalent 2009 H1N1 split inactivated virus vaccine alone; “Split+M2e5x”, vaccinated animals
with monovalent 2009 H1N1 split inactivated virus vaccine supplemented with M2e5x VLPs. Statistical signiﬁcance is indicated above each time point (* p≤0.05; † p≤0.
0 split a
t ared t
d
d
r
t
a
2
t
[
o
d
S
r
a
p
v
b
4
p
g
t
n
a
s
s
t
A
a
a
t01): S+M2vM2, M2+Split compared to M2 alone; S+M2vS: M2+Split compared to
o split alone; M2vN: M2 compared to unvaccinated animals; SvN: split alone comp
etection (100PFU per 1ml) is indicated with a dashed line.
ecline in peripheral CD4+ and CD8+ T cells, with their nadir occur-
ing one day post-infection rather than 2days (Fig. 5B–C). Similarly,
hese groups showed earlier granulocytosis (CD11b+ve; presum-
bly mainly neutrophils), with its peak on day 1 rather than day
(Fig. 5D). B cells (CD79A+) also showed moderate changes after
he challenge (data not shown). However, as described previously
19], B cells showed signiﬁcant ﬂuctuation and variability through-
ut the post-challenge period and did not demonstrate consistent
ifferences among the groups.
From day 7 on, vaccinated animals with M2e5x alone and
plit+M2e5x had a faster recovery of T cells (Fig. 5A). Signiﬁcant
ecovery in percentage of total counts was observed for both CD4
nd CD8 T cells (Fig. 5B–C). We have previously shown that total
eripheral leukocyte counts remain approximately constant after
iral challenge, so that the granulocytosis and lymphopenia are
oth relative and absolute changes in numbers [19].
. Discussion
In 2009, a novel A(H1N1) inﬂuenza virus entered the human
opulation, after decades of circulating in swine. Extensive anti-
enic drift between this strain and human inﬂuenza viruses meant
hat vaccines against contemporary human A(H1N1) strains did
ot confer protection against the swine-origin virus, leading to
global pandemic and the complete replacement of human sea-
onal A(H1N1) viruses by the A(H1N1)pdm09 strain. Although
easonal A(H1N1) strains no longer circulate in humans, viruses
hat are antigenically related to these strains still circulate in North
merican swine. There now exists a population of children, under
bout 6 years of age, who have not been exposed to or vaccinated
gainst seasonal A(H1N1) strains, although they may be immune
o A(H1N1)pdm09 viruses, so that there is a growing possibilitylone; S+M2vN: M2+Split compared to unvaccinated animals; M2vS: M2 compared
o unvaccinated animals. Error bars represent 95% conﬁdence intervals. The limit of
of a new pandemic or pseudopandemic if swine A(H1N1) viruses
enter this susceptible population. Here we show that, while ferrets
immunized with conventional split vaccine against H1N1pdm09
had no protection against infection with seasonal H1N1, supple-
menting the split vaccine with M2e5x VLPs conferred signiﬁcant
cross-protection against the seasonal virus.
Ferrets that were challenged with the seasonal A(H1N1)
strain BR/59 after immunization with a combination of split
A(H1N1)pdm09 vaccine and M2e5x VLPs had signiﬁcantly less
weight loss than ferrets that received split vaccine alone, or naïve
ferrets. Similarly, immunization with M2e5x VLPs appeared to
reduce inﬂammation, as measured by changes in peripheral blood
leukocytes. Due to the normal variations in temperature in fer-
rets, alterations in leukocytes can provide a more detailed view of
the inﬂammatory impact of inﬂuenza virus infection and vaccine
protection than fever measurement. In particular, ferrets receiv-
ing M2e5x VLPs showed a more rapid and complete recovery of T
cells (both CD4 and CD8) following the initial period of lymphope-
nia. Interestingly, both groups that received M2e5x VLPs showed
a more rapid initial loss of peripheral lymphocytes, with the low-
est levels of peripheral T cells occurring on day 1 instead of day
2 in these groups. This peripheral loss may reﬂect rapid trafﬁc-
king of primed inﬂuenza-speciﬁc T cells from the periphery to local
sites of infection, leading to earlier reduction of viral replication
through both humoral and cellular immune responses. Although
assessment of ferret cellular immunity is still in its infancy due
to a lack of ferret-reactive reagents, experiments are under way
to test the speciﬁc cellular immune response in vaccinated versus
unvaccinated ferrets.
We have previously shown signiﬁcant efﬁcacy of M2e vaccines
against inﬂuenza in mice, in which intramuscular vaccination with
M2e5x VLP induced M2e-speciﬁc humoral and cellular immune
472 N. Music et al. / Vaccine 34 (2016) 466–473
Fig. 5. Peripheral blood leukocyte subsets following infection. Ferrets were bled on days 0–7, 9, 11, and 13 relative to the day of viral challenge, and cells were stained and
analyzedbyﬂowcytometryasdescribed in the text. (A) T cells (CD3+), (B) THcells (CD3+/CD4+), (C) cytotoxic T lymphocytes (CD3+/CD8+), and (D)granulocytes (predominately
neutrophils (CD11b+) cells were measured and expressed relative to the day 0 values as 100%. “Naïve”, unvaccinated animals; “M2e5x”, vaccinated animals with M2e5x VLPs
alone; “Split”, vaccinated animals with monovalent 2009 H1N1 split inactivated virus vaccine alone; “Split+M2e5x”, vaccinated animals with monovalent 2009 H1N1 split
inactivated virus vaccine supplemented with M2e5x VLPs. Statistical signiﬁcance is indicated above each time point (* p≤0.05; † p≤0. 001): S+M2vM2, M2+Split compared
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esponses and conferred cross-protection as evidenced by lower
eight loss and higher survival rates [14]. Conventional split
nactivated vaccines confer protective immunity mainly through
irus-neutralizing antibodies targeting HA. In contrast, M2 immu-
ity does not induce virus-neutralizing antibodies and typically
ermits infection, even when the severity of the disease and the
xtent of virus shedding are reduced. As an alternative approach,
upplementing conventional vaccinationwithM2e5xVLPs showed
igniﬁcantly improvedcross-protection compared toeither vaccine
lone in mice.
In previous experiments in BALB/c mice, M2e5x VLP addition
lso demonstrated adjuvant effects in conjunction with split vac-
ine, increasing IgG antibody responses speciﬁc for split vaccine
irus by 2 to 4 fold compared to the split vaccine alone [23].
n those experiments, we observed that mice with M2e5x VLP-
upplemented split vaccination shifted the virus-speciﬁc immune
esponses toward T helper type 1 (Th1) IgG2a isotype antibod-
es, compared to the predominately Th2-associated IgG1 isotypeunvaccinated animals; M2vS: M2 compared to split alone; M2vN: M2 compared to
resent 95% conﬁdence intervals.
antibodies induced by split vaccine alone. In addition, M2e5x
VLP-supplemented split vaccination of mice induced Th1 type IFN-
 cytokine producing splenocytes and lung cells at signiﬁcantly
higher levels in response to in vitro stimulation with M2e peptide
or virus, than split alone vaccination [23].While this adjuvant effect
is a further potential beneﬁt to the combined M2e5x VLP-split vac-
cine approach, in the present experiments we offset the adjuvant
effects of M2e5x VLP by repeated vaccination with the split vaccine
alone.
Although mice are a convenient animal model to demonstrate
cross-protection after inﬂuenza M2e-based vaccination, ferrets are
considered to be the best animal model for predicting inﬂuenza
pathogenesis and vaccine efﬁcacy in humans, since the clinical
signs and immune response in these animals closely mimics those
in humans. Both seasonal A(H1N1) viruses, which circulated in
humans before 2010, and the pandemic variant of A(H1N1), which
is now prevalent in humans, infect ferrets without preadaptation
to this species, and it has been shown that in ferrets as in humans
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LPs showed signiﬁcant cross-protection, recovering body weight
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he M2e5x VLP alone group also showed some protective effects
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nﬂammation. Interestingly, we found that inclusion of M2e5x
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